Clinical Care Options for Hepatitis: HBV Highlights From EASL 2007

[Guest guest]

============================================================

Clinical Care Options for Hepatitis

------------------------------------------------------------

Conference Coverage From EASL 2007

http://lists.clinicaloptions.com/t/4601/54129/1206/0/

CCO Independent Conference Coverage of the 42nd Annual Meeting of the

European Association for the Study of the Liver*

April 11-15, 2007 | Barcelona, Spain

CCO AUDIO EXPERT HIGHLIGHTS

Listen to the CCO expert faculty quickly summarize the key issues in viral

liver disease highlighted at the conference!

This audio file is in mp3 format. You must be logged on to the

clinicaloptions.com site to listen to or download the mp3 file.

- M. Di Bisceglie, MD, FACP, discusses the top line HBV data

presented at the meeting with particular focus on combination therapy and

key outcomes in long-term follow-up of patients receiving

peginterferon-based treatment. (4 minutes) Download Audio

This Expert Highlight is located online at:

http://lists.clinicaloptions.com/t/4601/54129/1206/0/

CAPSULE SUMMARIES

Advances in HBV Treatment: 2007

- HBV Patients Treated With Lamivudine and Experiencing a Suboptimal

Response Benefit More From a Switch to Telbivudine Than Continued Lamivudine

Treatment

- Entecavir Associated With Greater HBV DNA Reduction vs Adefovir at Year

1 in Treatment-Naive HBeAg-Positive Chronic Hepatitis B Patients

- FibroScan Identified High Incidence of Fibrosis, Correlated With

Biochemical Liver Disease Measures, in Large Chronic HBV–Infected Population

- 9-Year Follow-up of Long-term Lamivudine Therapy in CHB Patients

Demonstrates Full Viral Suppression During First Year Predictive of Overall

Treatment Response

- Long-term Study of HBeAg-Positive Italian Patients With Chronic

Hepatitis B Reveals Prognostic Factors for Mortality

- GLOBE Study: Add or Switch to Adefovir a Viable Salvage Option for

Telbivudine-Treated Patients Exhibiting Virologic Breakthrough

- Long-term Lamivudine Therapy With or Without Adefovir Improves Outcome

of EVs in HBeAg-Negative Patients With Cirrhosis

- HBeAg Response Sustained in Most Patients Treated With Telbivudine or

Lamivudine in GLOBE Trial

- Entecavir Maintains High Genetic Barrier to Resistance Over 4 Years of

Treatment in Nucleoside-Naive Patients

- High Rates of Sustained Virologic Response in HBeAg-Negative Chronic

Hepatitis B Patients 3 Years Posttreatment With Peginterferon alfa-2a ±

Lamivudine

- Week 24 Interim Analysis During Treatment Shows Greater HBV DNA

Suppression With Peginterferon alfa-2a Plus Adefovir vs Peginterferon

alfa-2a Alone in HBV Patients

- No Long-term Benefit of Overlapping Lamivudine and Adefovir Prior to

Adefovir Monotherapy in Korean Patients With Lamivudine-Resistant HBV

- Nucleos(t)ide Analogue Resistance Pathways and Secondary Compensatory

Mutations Identified in Chronic Hepatitis B

- Modeling Based on Clinical and Laboratory Values Successful in

Predicting Mild Fibrosis in HBeAg-Positive and HBeAg-Negative Chronic

Hepatitis B Patients

- Phase III Data Suggest That Chronic Hepatitis B Patients Can Still Have

Significant Liver Disease Despite ALT < 2 x ULN

These Capsule Summaries are located online at:

http://lists.clinicaloptions.com/t/4601/54129/1207/0/

*CCO is an independent medical education company that provides

state-of-the-art medical information to healthcare professionals through

conference coverage and other educational programs.

------------------------------------------------------------

Coming soon: CME-Certified Expert Analyses

Physicians:

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care

Options, LLC.

Nurses:

Nursing contact hours provided through the cosponsorship of Postgraduate

Institute for Medicine and Clinical Care Options, LLC. Postgraduate

Institute for Medicine is accredited as a provider of continuing nursing

education by the American Nurses Credentialing Center's Commission on

Accreditation.

Supported by educational grants from Bristol-Myers Squibb Company,

Schering-Plough, Valeant Pharmaceuticals, and Vertex.

------------------------------------------------------------

ALSO AVAILABLE FROM CCO - Review Other HBV and HCV Programs

- New Treatment Data on HIV/Hepatitis Coinfection from the meeting in Los

Angeles

http://lists.clinicaloptions.com/t/4601/54129/1210/0/

- Review HBV and HCV Treatment Data from the 2006 Boston Meeting

http://lists.clinicaloptions.com/t/4601/54129/452/0/

------------------------------------------------------------